Insider Buying: Valeant Pharmaceuticals International Inc (VRX) Director Purchases C$327,450.00 in Stock

Valeant Pharmaceuticals International Inc (TSE:VRX) (NYSE:VRX) Director Schutter Richard Urbain De acquired 15,000 shares of the business’s stock in a transaction on Tuesday, May 15th. The shares were purchased at an average price of C$21.83 per share, with a total value of C$327,450.00.

Shares of Valeant Pharmaceuticals International stock opened at C$28.54 on Monday. Valeant Pharmaceuticals International Inc has a one year low of C$14.01 and a one year high of C$30.56.

Valeant Pharmaceuticals International (TSE:VRX) (NYSE:VRX) last posted its quarterly earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported C$1.24 earnings per share for the quarter, hitting the Zacks’ consensus estimate of C$1.24. Valeant Pharmaceuticals International had a net margin of 58.58% and a return on equity of 112.73%. The business had revenue of C$2.75 billion for the quarter, compared to analysts’ expectations of C$2.73 billion.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx, and U.S.

Receive News & Ratings for Valeant Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply